June 5th, 2019 – the Israeli company, NanoPass Technologies, a pioneer in the development and commercialization of nearly painless intradermal delivery solutions for vaccines and drugs, with its flagship product, being the only microneedle under 1mm to receive an FDA clearance to deliver substances below the surface of the skin, held meetings with key Chinese investors and VC’s, leading players from the medical industry and leading distributors at the CIIC. Among the companies NanoPass met with are Huaxing Capital, Ch – gemstone Capital, LePerle biotechnology, RCLH Medical Equipment, NJCX Medical Equipment, and many more.
Following long discussions, plans for collaboration with these players were established, and action item plans were prepared between NanoPass and every Chinese entity they met with. NanoPass will begin strategically growing their business in China after further discussions with newfound partnerships.
Actively bringing together the world’s most advanced, cutting-edge technologies from the world renowned “Start-up Nation” that is Israel to exhibitions at the CIIC, and key players from the Chinese market from a variety of technological sectors. The CIIC continuously supports and helps maintain connections between these large Chinese technology players and Israeli Companies with innovative technology, leading to prosperous collaborations between the parties.
